TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03415386
Drug: Combination of antiplatelet drugs and anticoagulants for at least one month
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
Study: NCT01146860
Drug: BNO 1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
Study: NCT01146860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
Study: NCT02306031
Drug: Prescribe ARTIFICIAL TEAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
Study: NCT02306031
Drug: Prescribe diclofenac sodium drop 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
Study: NCT01341392
Drug: amlodiopine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study: NCT04493840
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Study: NCT04493840
Drug: 5% Glucose Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Study: NCT00303134
Drug: Islet Cell Transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet Cell Transplantation for patients with type 1 diabetes mellitus
Study: NCT00160446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral Daily for 12 weeks
Study: NCT02463552
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Study: NCT02674854
Drug: PG324 Ophthalmic Solution 0.02%/0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Study: NCT03791515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion.
Study: NCT00344942
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a double spray into each nostril once daily
Study: NCT00913692
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
Study: NCT02582177
Drug: Candicort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply on the affected area and around it twice a day
Study: NCT02582177
Drug: Nizoral®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply on the affected area and around it twice a day
Study: NCT02582177
Drug: Baycuten N®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply on the affected area and around it twice a day
Study: NCT02582177
Drug: Canesten®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply on the affected area and around it twice a day
Study: NCT01767311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: biweekly (once every 2 weeks) administered as i.v. infusion
Study: NCT01059929
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Study: NCT04456153
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
Study: NCT04456153
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued standard of care therapy together with matching placebo
Study: NCT00251004
Drug: Mycophenolic Acid (MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 oral capsules of mycophenolic acid 360mg administered bid
Study: NCT02737072
Drug: LY2510924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT00251004
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Study: NCT04056897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
Study: NCT02674191
Drug: (150g Clindamycin/tds) for 1 week
Normalized name: Clindamycin for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic
Study: NCT02674191
Drug: (Cataflam 25mg), are prescribed post-operatively
Approvals — FDA: no, EMA: no, PMDA: no
Description: an analgesic
Study: NCT00557583
Drug: VBY 376
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of 50mg and higher or placebo will be evaluated.
Study: NCT04241185
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Study: NCT03181763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive inactive placebo on their second visit.
Study: NCT01847807
Drug: low dose Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02456662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
Study: NCT01244490
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02763969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002975
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01453387
Drug: MSC2015103B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
Study: NCT01453387
Drug: MSC2015103B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
Study: NCT01466543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02960893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
Study: NCT00954252
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral capsule, single dose
Study: NCT01173887
Drug: VCAP/AMP/VECP(mLSG15)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
Study: NCT03156127
Drug: BR-UPS 5 mg tablet, Inisia 5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
Study: NCT03268902
Drug: Azithromycin Oral Liquid Product
Normalized name: azithromycin Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Study: NCT01479556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg BID p.o.
Study: NCT02176720
Drug: FDOPA PET
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
Study: NCT03078530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a pill with inactive ingredients
Study: NCT03078530
Drug: Visbiome
Normalized name: Visbiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a probiotic mixture available to randomized study participants, starting with subject 29
Study: NCT03078530
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a probiotic mixture available to the first 28 subjects randomized to the study
Study: NCT00634192
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1x300mg/d inhaled
Study: NCT00634192
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2x300mg/d inhaled
Study: NCT03268902
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Study: NCT02842086
Drug: F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02842086
Drug: F/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00283400
Drug: 25% human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
Study: NCT00768105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing to match AZD1656
Study: NCT03208218
Drug: SYP-1512
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
Study: NCT02298595
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200, 250, 300, or 350 mg/day by mouth every day
Study: NCT03610646
Drug: MYL-1701P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol.
Study: NCT00282347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided as a sterile solution for injection.
Study: NCT01855321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
Study: NCT00282347
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02980029
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
Study: NCT03596086
Drug: ADV/HSV-tk (gene therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study: NCT02490527
Drug: Simvastatin (40mg)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A cholesterol-lowering medication that blocks the production of cholesterol.
Study: NCT04242368
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
Study: NCT04242368
Drug: Hypertonic Nasal Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
Study: NCT03275454
Drug: BIVV009 6.5 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
Study: NCT03275454
Drug: BIVV009 7.5 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
Study: NCT00871507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension/solution and Placebo capsule administered as single doses
Study: NCT03451227
Drug: Remifentanil Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
Study: NCT02147262
Drug: doxycycline orally, 100 mg, bid, 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004904
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02147262
Drug: doxycycline orally, 100 mg, bid, 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03371680
Drug: Injection of 1-13 Carbon Leucine and deuterated water
Normalized name: Sodium salt of carbonic acid
DrugBank: Sodium carbonate (DB09460)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
Study: NCT04946474
Drug: Xingnaojing injection + Shuxuetong oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
Study: NCT01300533
Drug: BIND-014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183103
Drug: meloxicam rapid release tablet, 12mg, UH AC62MU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003273
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003273
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03612713
Drug: Placebo First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Study: NCT00925938
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02858297
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
Study: NCT01099709
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 10-mg tablet x 1 dose taken with food.
Study: NCT01099709
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
Study: NCT01031225
Drug: STA 9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Study: NCT00117884
Drug: 851B
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study: NCT01103401
Drug: Drug: Tobramycin 0.3% - Dexamethasone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop four times per day
Study: NCT01103401
Drug: Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
Study: NCT03768557
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline (200mg)
Study: NCT00695604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via MDI.
Study: NCT00376714
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02531971
Drug: Intravenous fentanyl citrate
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 micrograms (2 millilitres) via intravenous injection
Study: NCT02531971
Drug: Duragesic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Study: NCT02531971
Drug: Mylan generic fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Study: NCT01389362
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sachets to be taken daily
Study: NCT00552617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered
Study: NCT02125617
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day
Study: NCT00943553
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
Study: NCT01803035
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00154336
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02149212
Drug: Phlebotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminaftone -- 75 mg BID
Study: NCT00393952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00403754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT00338377
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
Study: NCT02225054
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 0.9%
Study: NCT02093650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy bean oil
Study: NCT01528540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will include placebo.
Study: NCT00817778
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Study: NCT00817778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Study: NCT04715737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo intranasally